HF-158K1 by HighField Biopharmaceuticals for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

Opinion | CDC Advisors’ Infection Control Guidance Leaves Us Unprotected

Ross is a nurse and co-president of a nurses’ union. Thomason is an industrial hygienist. Earlier this month, the CDC’s Healthcare Infection Control Practices Advisory

November 30, 2023

Study sheds new light on the heterogeneity of type 2 diabetes

A landmark study by the German Diabetes Center (DDZ), published in The Lancet Diabetes & Endocrinology, sheds new light on the heterogeneity of type 2

March 19, 2024

Global gap in diabetes prevalence and treatment has widened since 1990

Global diabetes rates have surged, particularly in low-resource areas, revealing critical gaps in treatment access and highlighting the need for improved care.

November 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.